Cullinan Therapeutics, Inc.

NASDAQ:CGEM

Medical - Pharmaceuticals

Healthcare
$9.01 +4.29%

+$0.62 today

Market cap
$584.94M
Beta
0.01
P/E (TTM)
-4.0
EPS (TTM)
-$3.73
52W Low $5.68High $16.74

Volume 1.06M

Average 0.99M

CGEM Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Cullinan Therapeutics, Inc.NASDAQ: CGEM

Operating Expenses · Q1 FY2026 · quarter ended Mar 2026

Operating expenses dips below year-ago levels

Q1 FY2026 operating expenses of $53.7M fell 2.4% year over year, behind the +15.1% change in trailing-twelve-month operating expenses. Sequentially, it fell 2.8% from the prior quarter.

Context

  • Operating expenses increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -2.4% toward the trailing-twelve-month pace of +15.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$53.7M-2.8% QoQ
Last fiscal yearDec 2025
$241.65M+22.9% YoY
LTMMar 2026
$240.35M+15.1% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-2.4%——
1 year+22.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
241.65M USD
Year-over-year change
+22.9%
4-year CAGR
+29.1%

Operating Expenses vs competitors

How CGEM compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +15.1% is the 4th highest of 11, against a peer median of +5.8%.
CGEM Competitors
Operating Expenses for CGEM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LEGNLegend Biotech CorporationLTM Sep 2026$740.02M USD-0.1%+14.3%54.5%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$317.52M USD+142.5%+109.8%45.2%
XNCRXencor, Inc.LTM Jun 2026$261.54M USD+14.7%+83.3%249.1%
IMTXImmatics N.V.LTM Mar 2026€250M EUR+22.1%+17.2%670.3%
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$240.35M USD+15.1%——
ADCTADC Therapeutics S.A.LTM Mar 2026$190.31M USD-2.8%-18.0%240.4%
MGNXMacroGenics, Inc.LTM Mar 2026$173.51M USD-10.6%-12.1%110.5%
JANXJanux Therapeutics, Inc.LTM Mar 2026$168.69M USD+127.4%+30.3%780.5%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$156.87M USD+11.7%+68.8%—
ALXOALX Oncology Holdings Inc.LTM Mar 2026$91.02M USD-33.2%-6.5%—
CGENCompugen Ltd.LTM Mar 2026$33.28M USD-2.6%-8.4%45.8%
Peer median (excluding CGEM) —+5.8%+15.8%175.4%

Competitors are the stored peer set for CGEM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue18.94M0000
Cost of Revenue000306K0
Gross Profit18.94M00(306K)0
Gross Margin100.0%————
Research & Development57.75M91.95M148.16M142.9M187.4M
Selling, General & Admin29.15M40.19M42.49M53.71M54.25M
Operating Expenses86.9M(144.65M)191.09M196.61M241.65M
Depreciation & Amortization53K93K310K306K311K
EBITDA(67.43M)(132.04M)(190.34M)(167.15M)(219.57M)
EBITDA Margin-356.0%————
Operating Income(67.95M)144.65M(191.09M)(196.92M)(241.65M)
Operating Margin-358.7%————
Interest Income477K6.61M21.63M29.66M22.21M
Interest Expense00000
Other Income / Expenses469K6.67M21.87M29.46M21.77M
Income Before Tax(67.49M)151.32M(169.22M)(167.46M)(219.88M)
Pre-Tax Margin-356.3%————
Income Tax Expense042.12M(14.12M)117K0
Net Income(65.57M)111.21M(153.16M)(167.38M)(219.88M)
Net Margin-346.1%————
EPS (Basic)(1.48)2.46(3.69)(3.11)(3.72)
EPS (Diluted)(1.48)2.38(3.69)(3.11)(3.72)
Weighted Avg Shares44.29M45.16M41.51M53.77M59.05M
Weighted Avg Shares (Diluted)44.29M46.64M41.55M53.77M59.05M

Cullinan Therapeutics, Inc.

NASDAQ:CGEM

Intrinsic Alpha fair value

Locked

Current Price

$9.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.